Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer acetate new formulation versus placebo in relapsing-remitting multiple sclerosis
2011-005550-57Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Glatiramer acetate with Placebo (2 arms). Primary endpoint: Total number of confirmed relapses. Started Feb 2012; status: terminated.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2011-005550-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005550-57.